These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20153964)

  • 1. Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.
    Morriello GJ; Mills SG; Johnson T; Reibarkh M; Chicchi G; DeMartino J; Kurtz M; Davies P; Tsao KL; Zheng S; Tong X; Carlson E; Townson K; Tattersall FD; Wheeldon A; Boyce S; Collinson N; Rupniak N; Moore S; DeVita RJ
    Bioorg Med Chem Lett; 2010 Mar; 20(6):2007-12. PubMed ID: 20153964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.
    Morriello GJ; Devita RJ; Mills SG; Young JR; Lin P; Doss G; Chicchi GG; Demartino J; Kurtz MM; Tsao KL; Carlson E; Townson K; Wheeldon A; Boyce S; Collinson N; Rupniak N; Moore S
    Bioorg Med Chem; 2008 Mar; 16(5):2156-70. PubMed ID: 18248994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.
    Morriello GJ; Chicchi G; Johnson T; Mills SG; Demartino J; Kurtz M; Tsao KL; Zheng S; Tong X; Carlson E; Townson K; Wheeldon A; Boyce S; Collinson N; Rupniak N; Devita RJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5925-32. PubMed ID: 20729082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
    Tung YS; Coumar MS; Wu YS; Shiao HY; Chang JY; Liou JP; Shukla P; Chang CW; Chang CY; Kuo CC; Yeh TK; Lin CY; Wu JS; Wu SY; Liao CC; Hsieh HP
    J Med Chem; 2011 Apr; 54(8):3076-80. PubMed ID: 21434659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine.
    Lin P; Chang L; Devita RJ; Young JR; Eid R; Tong X; Zheng S; Ball RG; Tsou NN; Chicchi GG; Kurtz MM; Tsao KL; Wheeldon A; Carlson EJ; Eng W; Burns HD; Hargreaves RJ; Mills SG
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5191-8. PubMed ID: 17637506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.
    Shan W; Balog A; Nation A; Zhu X; Chen J; Cvijic ME; Geng J; Rizzo CA; Spires T; Attar RM; Obermeier M; Traeger S; Dai J; Zhang Y; Galella M; Trainor G; Vite GD; Gavai AV
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5707-5711. PubMed ID: 27836399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly constrained bicyclic VLA-4 antagonists.
    Chang LL; Truong Q; Doss GA; MacCoss M; Lyons K; McCauley E; Mumford R; Forrest G; Vincent S; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2007 Feb; 17(3):597-601. PubMed ID: 17118652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
    Huscroft IT; Carlson EJ; Chicchi GG; Kurtz MM; London C; Raubo P; Wheeldon A; Kulagowski JJ
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2008-12. PubMed ID: 16413782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists.
    Vu CB; Kiesman WF; Conlon PR; Lin KC; Tam M; Petter RC; Smits G; Lutterodt F; Jin X; Chen L; Zhang J
    J Med Chem; 2006 Nov; 49(24):7132-9. PubMed ID: 17125265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane derivatives: orally active, potent, and selective prostaglandin D2 receptor antagonists.
    Tsuri T; Honma T; Hiramatsu Y; Okada T; Hashizume H; Mitsumori S; Inagaki M; Arimura A; Yasui K; Asanuma F; Kishino J; Ohtani M
    J Med Chem; 1997 Oct; 40(22):3504-7. PubMed ID: 9357516
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist.
    Luo G; Chen L; Hu S; Huang Y; Mattson G; Iben LG; Russell JW; Clarke WJ; Hogan JB; Antal-Zimanyi I; Poindexter GS
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3814-7. PubMed ID: 23726344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonamide derivatives of bridgehead substituted bicyclo[4.2.1]nonanes as gamma-secretase inhibitors.
    Sparey T; Clarke E; Hannam J; Harrison T; Madin A; Shearman M; Sohal B
    Bioorg Med Chem Lett; 2008 Jan; 18(1):375-9. PubMed ID: 18061448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates.
    Cui JJ; Araldi GL; Reiner JE; Reddy KM; Kemp SJ; Ho JZ; Siev DV; Mamedova L; Gibson TS; Gaudette JA; Minami NK; Anderson SM; Bradbury AE; Nolan TG; Semple JE
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2925-30. PubMed ID: 12270176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK(1) receptor antagonists.
    Sabbatini FM; Di Fabio R; Griffante C; Pentassuglia G; Zonzini L; Melotto S; Alvaro G; Capelli AM; Pippo L; Perdona' E; St Denis Y; Costa S; Corsi M
    Bioorg Med Chem Lett; 2010 Jan; 20(2):623-7. PubMed ID: 19963378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydroindolizinone NK1 antagonists.
    Bao J; Lu H; Morriello GJ; Carlson EJ; Wheeldon A; Chicchi GG; Kurtz MM; Tsao KL; Zheng S; Tong X; Mills SG; DeVita RJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2354-8. PubMed ID: 20188553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
    J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
    Stepan AF; Subramanyam C; Efremov IV; Dutra JK; O'Sullivan TJ; DiRico KJ; McDonald WS; Won A; Dorff PH; Nolan CE; Becker SL; Pustilnik LR; Riddell DR; Kauffman GW; Kormos BL; Zhang L; Lu Y; Capetta SH; Green ME; Karki K; Sibley E; Atchison KP; Hallgren AJ; Oborski CE; Robshaw AE; Sneed B; O'Donnell CJ
    J Med Chem; 2012 Apr; 55(7):3414-24. PubMed ID: 22420884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement.
    Eastwood P; Gonzalez J; Paredes S; Fonquerna S; Cardús A; Alonso JA; Nueda A; Domenech T; Reinoso RF; Vidal B
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1634-7. PubMed ID: 20138516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.